Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $44.30 USD
Change Today +0.01 / 0.02%
Volume 943.0K
XON On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 3:41 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

intrexon corp (XON) Snapshot

Open
$45.01
Previous Close
$44.29
Day High
$45.50
Day Low
$43.51
52 Week High
08/6/15 - $69.45
52 Week Low
10/9/14 - $15.55
Market Cap
5.1B
Average Volume 10 Days
1.9M
EPS TTM
$-1.29
Shares Outstanding
114.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTREXON CORP (XON)

intrexon corp (XON) Related Businessweek News

View More BusinessWeek News

intrexon corp (XON) Details

Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; cell systems informatics; RheoSwitch inducible gene switch; AttSite Recombinases; protein engineering; mAbLogix; and laser-enabled analysis and processing. Intrexon Corporation has collaboration agreements with ZIOPHARM Oncology, Inc.; Synthetic Biologics, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; AquaBounty Technologies, Inc.; S & I Ophthalmic, LLC; Biological & Popular Culture, Inc.; OvaXon, LLC; Intrexon Energy Partners, LLC; and Persea Bio, LLC; and strategic collaboration and licensing agreement with Merck Serono S.A. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

480 Employees
Last Reported Date: 03/2/15
Founded in 1998

intrexon corp (XON) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: --
Chief Financial Officer
Total Annual Compensation: $382.2K
Chief Operating Officer
Total Annual Compensation: $2.3M
Head of Health Sector and Senior Vice Preside...
Total Annual Compensation: $485.3K
Senior Vice President of Energy Sector
Total Annual Compensation: $341.0K
Compensation as of Fiscal Year 2014.

intrexon corp (XON) Key Developments

ZIOPHARM Oncology, Inc., Intrexon Corporation and The University of Texas M. D. Anderson Cancer Center Enter into Research and Development Agreement

On August 17, 2015, ZIOPHARM Oncology, Inc., Intrexon Corporation and The University of Texas M. D. Anderson Cancer Center entered into a research and development agreement to formalize the scope and process for the transfer by MD Anderson, pursuant to the terms of the License, of certain existing research programs and related technology rights, as well as the terms and conditions for future collaborative research and development of new and ongoing research programs. Pursuant to the Research and Development Agreement, the company, Intrexon and MD Anderson have agreed to form a joint steering committee that will oversee and manage the new and ongoing research programs. As provided under the License, the company will provide funding for research and development activities of MD Anderson in support of certain research programs under the Research and Development Agreement for a period of three years and in an amount of no less than $15 million and no greater than $20 million annually.

Intrexon Seeks Acquisitions

Intrexon Corporation (NYSE:XON) is looking for acquisition opportunities. Intrexon commenced an underwritten public offering of shares of its common stock and intends to use the net proceeds from this offering for general corporate purposes as well as for strategic acquisitions or investments.

Intrexon Corporation Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Intrexon Corporation announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $44.891 million against $11.787 million a year ago. Operating loss was $17.430 million against $18.082 million a year ago. Loss before income taxes was $40.560 million against $53.218 million a year ago. Net loss was $41.494 million against $52.935 million a year ago. Net loss attributable to the company was $40.663 million against $52.043 million a year ago. Net loss per share, basic and diluted was $0.37 against $0.53 a year ago. Pro forma net income attributable to the company was $0.882 million. Pro forma net income attributable to the company’s per share, basic was $0.01. LBITDA was $35.607 million against $50.364 million a year ago. Adjusted EBITDA was $54.425 million or $0.49 per diluted share against adjusted LBITDA $10.425 million or $0.11 per diluted share a year ago. For the six months, the company reported total revenues of $78.740 million against $19.641 million a year ago. Operating loss was $104.553 million against $35.954 million a year ago. Loss before income taxes was $13.961 million against $49.663 million a year ago. Net loss was $15.690 million against $49.686 million a year ago. Net loss attributable to the company was $13.566 million against $47.928 million a year ago. Net loss per share, basic and diluted was $0.13 against $0.49 a year ago. Pro forma net income attributable to the company was $27.979 million. Pro forma net income attributable to the company’s per share, basic was $0.26. LBITDA was $3.944 million against $44.146 million a year ago. Adjusted EBITDA was $39.787 million or $0.36 per diluted share against $7.160 million or $0.07 per diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XON:US $44.16 USD -0.13

XON Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexion Pharmaceuticals Inc $177.87 USD +4.33
Photon Technology International Inc $0.0003 USD 0.00
MorphoSys AG €63.94 EUR +1.24
XOMA Corp $0.81 USD +0.01
View Industry Companies
 

Industry Analysis

XON

Industry Average

Valuation XON Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 37.0x
Price/Book 10.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 37.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTREXON CORP, please visit www.dna.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.